Occam Places Dan Kemp as CEO of Shinobi Therapeutics
Shinobi Therapeutics, a newly formed iPS cell therapy company created through the merger of Thyas Ltd (Japan) and Evade Biotechnology (USA) has appointed Dan Kemp as CEO. Founded on the basis of highly innovative iPSC and immune evasion research out of the University of Kyoto and UCSF, the enterprise was funded by key investors including F-Prime Capital and Eight Roads.
Previously, Dan served as CEO of Wugen Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies. Prior to Wugen, Dan held a variety of senior Business Development and R&D leadership roles with Takeda and Novartis.
Dan received his BSc and Ph.D. in molecular pharmacology from the University of Kent (UK).
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.